Second-Line Trastuzumab Deruxtecan Yields 23-Month Progression-Free Survival in Gastroesophageal Cancer
A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan following ...


